Ranbaxy’s Ongoing Issues With FDA Continue Novartis Windfall With Diovan

Ranbaxy’s newest manufacturing site at Mohali, India, is prohibited by FDA from shipping products to the U.S., further delaying approval of generic valsartan. Novartis has recently revised its sales guidance due to lower than expected generic sales erosion in the U.S. this year.